Physician
Sangisetty, Arunavathi
Sangisetty, Arunavathi was paid $365K by Medicaid between Jan 2018 and Feb 2024, across 30 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 46% of everything it billed.
33Billing provider infoSANGISETTY, ARUNAVATHI
HOUMA, LA 70360
HOUMA, LA 70360
33aNPI1215953658assigned 07/15/2006
33bProvider typePediatrics Physician
28Total paid$365K
24GClaims11,652
24DCodes billed30
24AFirst – last monthJan 2018 – Feb 2024
Compared with peers
Next to other Pediatrics Physician providers in Louisiana
Rank by total paid#121 of 230
Median peer was paid$429K
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,044 | $39K | |
| 2019 | 2,221 | $75K | |
| 2020 | 1,567 | $56K | |
| 2021 | 3,101 | $92K | |
| 2022 | 2,102 | $71K | |
| 2023 | 1,514 | $32K | |
| 2024incomplete | 103 | $877.37 |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 46% | 4,653 | 3,853 | $167K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 34% | 2,150 | 1,860 | $126K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 4.4% | 74 | 46 | $16K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 2.1% | 137 | 132 | $8K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.0% | 117 | 108 | $7K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.8% | 25 | 17 | $7K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1.7% | 625 | 535 | $6K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.5% | 721 | 465 | $5K |
| 92551 | 1.2% | 741 | 669 | $4K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.0% | 102 | 81 | $4K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 70 | 69 | $3K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 51 | 43 | $2K |
18 more codes
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 87 | $2K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 230 | $2K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 161 | $2K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 68 | $1K |
| 99173 | <1% | 778 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 120 | $1K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 14 | $782.76 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 35 | $456.17 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 35 | $421.08 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 29 | $308.97 |
| 81002 | <1% | 169 | $260.44 | |
| 85018 | <1% | 16 | $37.76 | |
| 81025 | <1% | 14 | $31.55 | |
| 94761 | <1% | 250 | $16.83 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15 | $8.04 |
| 90670 | 0% | 12 | $0.00 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 137 | $0.00 |
| 96127 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.